In this edition of Cardiovascular News (issue 48, US edition), we report on the top stories from TCT 2017—including: ORBITA, CULPRIT-SHOCK and the cost-effectiveness data from PARTNER 2A/SAPIEN 3. We also have commentaries from leading interventional cardiologists, such as Robert Yeh, and profile Justin Davies.
[pdfviewer width=”100%” height=”940px” beta=”true”]https://cardiovascularnews.com/wp-content/uploads/sites/14/2018/02/48-Cardiovascular-News-US.pdf[/pdfviewer]
